Nektar Therapeutics Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata

Reuters03-04

Nektar <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata

Nektar Therapeutics outlined its immunology and inflammation pipeline at the TD Cowen 46th Annual Health Care Conference, highlighting rezpegaldesleukin, a Phase 2 selective IL-2 agonist designed to stimulate regulatory T cells. The company said rezpegaldesleukin is being evaluated in Phase 2b studies in atopic dermatitis and alopecia areata, and in a Phase 2 trial in stage 3 type 1 diabetes, and described a proposed Phase 3 trial design in atopic dermatitis. Nektar also provided an overview of earlier-stage programs, including TNFR2 agonist antibody candidates and partnered studies of NKTR-255 in oncology, and reported an expected cash and cash equivalents balance of $240 million at the end of 2025 with runway into the second quarter of 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616484556?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 22:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616484556","market":"nz","top_or_hot":-1,"title":"Nektar Therapeutics Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nektar Therapeutics outlined its immunology and inflammation pipeline at the TD Cowen 46th Annual Health Care Conference, highlighting rezpegaldesleukin, a Phase 2 selective IL-2 agonist designed to stimulate regulatory T cells. The company said rezpegaldesleukin is being evaluated in Phase 2b studies in atopic dermatitis and alopecia areata, and in a Phase 2 trial in stage 3 type 1 diabetes, and described a proposed Phase 3 trial design in atopic dermatitis. Nektar also provided an overview of earlier-stage programs, including TNFR2 agonist antibody candidates and partnered studies of NKTR-255 in oncology, and reported an expected cash and cash equivalents balance of $240 million at the end of 2025 with runway into the second quarter of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nektar Therapeutics Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNektar Therapeutics Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-04 22:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Nektar Therapeutics outlined its immunology and inflammation pipeline at the TD Cowen 46th Annual Health Care Conference, highlighting rezpegaldesleukin, a Phase 2 selective IL-2 agonist designed to stimulate regulatory T cells. The company said rezpegaldesleukin is being evaluated in Phase 2b studies in atopic dermatitis and alopecia areata, and in a Phase 2 trial in stage 3 type 1 diabetes, and described a proposed Phase 3 trial design in atopic dermatitis. Nektar also provided an overview of earlier-stage programs, including TNFR2 agonist antibody candidates and partnered studies of NKTR-255 in oncology, and reported an expected cash and cash equivalents balance of $240 million at the end of 2025 with runway into the second quarter of 2027. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKTR","symbol_name":"内克塔治疗","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL6g7Vh0:1","article_id":"2616484556","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616484556","pubTimestamp":1772634010,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Nektar Therapeutics outlined its immunology and inflammation pipeline at the TD Cowen 46th Annual Health Care Conference, highlighting rezpegaldesleukin, a Phase 2 selective IL-2 agonist designed to stimulate regulatory T cells. The company said rezpegaldesleukin is being evaluated in Phase 2b studies in atopic dermatitis and alopecia areata, and in a Phase 2 trial in stage 3 type 1 diabetes, and described a proposed Phase 3 trial design in atopic dermatitis. Nektar also provided an overview of earlier-stage programs, including TNFR2 agonist antibody candidates and partnered studies of NKTR-255 in oncology, and reported an expected cash and cash equivalents balance of $240 million at the end of 2025 with runway into the second quarter of 2027. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKTR":"内克塔治疗","BK4007":"制药"},"translate_title":"Nektar Therapeutics发表Rezpegaldesleukin Treg疗法治疗特应性皮炎和斑秃","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NKTR":0.9},"content_text":"Nektar Therapeutics Publishes Presentation on Rezpegaldesleukin Treg Therapy for Atopic Dermatitis and Alopecia Areata\n    \n\n        Nektar Therapeutics outlined its immunology and inflammation pipeline at the TD Cowen 46th Annual Health Care Conference, highlighting rezpegaldesleukin, a Phase 2 selective IL-2 agonist designed to stimulate regulatory T cells. The company said rezpegaldesleukin is being evaluated in Phase 2b studies in atopic dermatitis and alopecia areata, and in a Phase 2 trial in stage 3 type 1 diabetes, and described a proposed Phase 3 trial design in atopic dermatitis. Nektar also provided an overview of earlier-stage programs, including TNFR2 agonist antibody candidates and partnered studies of NKTR-255 in oncology, and reported an expected cash and cash equivalents balance of $240 million at the end of 2025 with runway into the second quarter of 2027. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief on March 04, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616484556","isCrawlerRequest":true}